Literature DB >> 11741828

Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C.

M Brockington1, Y Yuva, P Prandini, S C Brown, S Torelli, M A Benson, R Herrmann, L V Anderson, R Bashir, J M Burgunder, S Fallet, N Romero, M Fardeau, V Straub, G Storey, C Pollitt, I Richard, C A Sewry, K Bushby, T Voit, D J Blake, F Muntoni.   

Abstract

The limb girdle and congenital muscular dystrophies (LGMD and CMD) are characterized by skeletal muscle weakness and dystrophic muscle changes. The onset of symptoms in CMD is within the first few months of life, whereas in LGMD they can occur in late childhood, adolescence or adult life. We have recently demonstrated that the fukutin-related protein gene (FKRP) is mutated in a severe form of CMD (MDC1C), characterized by the inability to walk, leg muscle hypertrophy and a secondary deficiency of laminin alpha2 and alpha-dystroglycan. Both MDC1C and LGMD2I map to an identical region on chromosome 19q13.3. To investigate whether these are allelic disorders, we undertook mutation analysis of FKRP in 25 potential LGMD2I families, including some with a severe and early onset phenotype. Mutations were identified in individuals from 17 families. A variable reduction of alpha-dystroglycan expression was observed in the skeletal muscle biopsy of all individuals studied. In addition, several cases showed a deficiency of laminin alpha2 either by immunocytochemistry or western blotting. Unexpectedly, affected individuals from 15 families had an identical C826A (Leu276Ileu) mutation, including five that were homozygous for this change. Linkage analysis identified at least two possible haplotypes in linkage disequilibrium with this mutation. Patients with the C826A change had the clinically less severe LGMD2I phenotype, suggesting that this is a less disruptive FKRP mutation than those found in MDC1C. The spectrum of LGMD2I phenotypes ranged from infants with an early presentation and a Duchenne-like disease course including cardiomyopathy, to milder phenotypes compatible with a favourable long-term outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11741828     DOI: 10.1093/hmg/10.25.2851

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  130 in total

1.  Differential glycosylation of α-dystroglycan and proteins other than α-dystroglycan by like-glycosyltransferase.

Authors:  Peng Zhang; Huaiyu Hu
Journal:  Glycobiology       Date:  2011-09-19       Impact factor: 4.313

Review 2.  Genetic neuromuscular disease.

Authors:  Mary M Reilly; Michael G Hanna
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

3.  RPTPζ/phosphacan is abnormally glycosylated in a model of muscle-eye-brain disease lacking functional POMGnT1.

Authors:  C A Dwyer; E Baker; H Hu; R T Matthews
Journal:  Neuroscience       Date:  2012-06-19       Impact factor: 3.590

4.  FKRP mutations, including a founder mutation, cause phenotype variability in Chinese patients with dystroglycanopathies.

Authors:  Xiaona Fu; Haipo Yang; Cuijie Wei; Hui Jiao; Shuo Wang; Yanling Yang; Chunxi Han; Xiru Wu; Hui Xiong
Journal:  J Hum Genet       Date:  2016-07-21       Impact factor: 3.172

5.  Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycan.

Authors:  Atsushi Kuga; Motoi Kanagawa; Atsushi Sudo; Yiumo Michael Chan; Michiko Tajiri; Hiroshi Manya; Yamato Kikkawa; Motoyoshi Nomizu; Kazuhiro Kobayashi; Tamao Endo; Qi L Lu; Yoshinao Wada; Tatsushi Toda
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

6.  Mislocalization of fukutin protein by disease-causing missense mutations can be rescued with treatments directed at folding amelioration.

Authors:  Masaji Tachikawa; Motoi Kanagawa; Chih-Chieh Yu; Kazuhiro Kobayashi; Tatsushi Toda
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

7.  The Role of Nonglycolytic Glucose Metabolism in Myocardial Recovery Upon Mechanical Unloading and Circulatory Support in Chronic Heart Failure.

Authors:  Rachit Badolia; Dinesh K A Ramadurai; E Dale Abel; Peter Ferrin; Iosif Taleb; Thirupura S Shankar; Aspasia Thodou Krokidi; Sutip Navankasattusas; Stephen H McKellar; Michael Yin; Abdallah G Kfoury; Omar Wever-Pinzon; James C Fang; Craig H Selzman; Dipayan Chaudhuri; Jared Rutter; Stavros G Drakos
Journal:  Circulation       Date:  2020-04-30       Impact factor: 29.690

Review 8.  The utility of muscle biopsy.

Authors:  David Lacomis
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

Review 9.  The dystroglycanopathies: the new disorders of O-linked glycosylation.

Authors:  Paul T Martin
Journal:  Semin Pediatr Neurol       Date:  2005-09       Impact factor: 1.636

10.  Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats.

Authors:  Paul T Martin; G Diane Shelton; Peter J Dickinson; Beverly K Sturges; Rui Xu; Richard A LeCouteur; Ling T Guo; Robert A Grahn; Harriet P Lo; Kathryn N North; Richard Malik; Eva Engvall; Leslie A Lyons
Journal:  Neuromuscul Disord       Date:  2008-11-05       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.